Genzyme Corporate Research Search Genzyme Websites
Patients and FamiliesHealth Care ProfessionalsAbout Genzyme Therapeutics
Fabry Community HomeFabry Community
Health Care Professional Overview
About Fabry Disease
Current Treatments
The Fabry Registry
Genzyme Support
Resources
Submit Medical Questions
Request Materials
Publications
Events Calendar
Related Links

Fabry Disease Publications

Since its identification in 1898, there have been several hundred papers published on Fabry disease. The selected bibiography below includes selected full-text articles and Pubmed abstracts by specialty on Fabry disease. Copies of articles listed below can also be requested via email, mail, or fax:

Genzyme Therapeutics
Medical Information
One Kendall Square
Cambridge, MA 02139 U.S.A.
617-591-7178 or 800-737-3642 (fax)
Email form

Fabry Disease Selected Bibliography

General Interest

Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw Hill, 2001;3733-3774.

MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750-760.

MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769-775.

Peters FP, Sommer A, Vermeulen A, Cheriex EC, Kho TL. Fabry’s disease: a multidisciplinary disorder. Postgrad Med J. 1997;73:710-712.

Renal Complications

Grunfeld J, Chauveau D, Levy M. Anderson-Fabry disease: its place among other genetic causes of renal disease. J Am Soc Nephrol. 2002;13 Suppl 2:S126-129.

Grunfeld J, Lidove O, Joly D, Barbey F. Renal disease in Fabry patients. J Inherit Metab Dis 2001;24 Suppl 2:71-74.

Meroni M, Sessa A, Battini G, Tazzari S, Torri Tarelli L. Kidney involvement in Anderson-Fabry disease. Contrib Nephrol. 1997;122:178-184.

Sessa A, Meroni M, Battini G, et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis. 2001;24 Suppl 2:66-70.

Cardiac Complications

Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol. 1986;7:1157-1161.

Linhart A, Lubanda JC, Palecek T, et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis. 2001;24 Suppl 2:75-83; discussion 65.

Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J. 2000;139:1101-1108.

Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288-293.

Download PDF

von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med. 1991;324:395-399.

Neurological Complications

Grewal RP. Stroke in Fabry's disease. J Neurol. 1994;241:153-156.

Hilz MJ, Stemper B, Kolodny EH. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain. 2000;84:361-365.

Download PDF

Morgan SH, Rudge P, Smith SJ, et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency) -- investigation of symptomatic and presymptomatic patients. Q J Med. 1990;75:491-507.

Ophthalmologic Complications

Bao LL, Guo LL, Li SN, et al. A family with Fabry's disease. Ocular manifestations and transmission electron microscopic examination of a skin lesion biopsy. Chin Med J (Engl). 1990;103:134-141.

Lester M, Sodi A, Occella C, Vittone P. Ocular findings in Fabry's disease. Contrib Nephrol. 2001;136:260-262.

Vinals AF, Kenyon KR. Corneal manifestations of metabolic diseases. Int Ophthalmol Clin. 1998;38:141-153.

Dermatological Manifestations

Schiller PI, Itin PH. Angiokeratomas: an update. Dermatology. 1996;193:275-282.

Keyword: 
Search In: 
New Page 1
Fabry Voices
""

More Fabry patient profiles
Fabry Registry

First Symptoms to Diagnosis

Data from the Fabry Registry confirms the large gap between the average age of symptoms onset (10.5) and diagnosis of Fabry disease (28.5). To learn more about the importance of the Fabry Registry click here.

Contact Information
Genzyme Therapeutics
500 Kendall Street
Cambridge, MA 02142
617 768 9000
800 745 4447

Genzyme Europe BV
Gooimeer 10
1411 DD Naarden
The Netherlands
31 35 699 1200
Contact Genzyme


Terms and Conditions of Use | Privacy Policy | © 2003-2008 Genzyme Corporation. All rights reserved.| © Fabr/US/P219/08/05
Genzyme Therapeutics